The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program
<p>Abstract</p> <p>Background</p> <p>In 1996, the National Cancer Institute hosted an international workshop to develop criteria to identify patients with colorectal cancer who should be offered microsatellite instability (MSI) testing due to an increased risk for Hered...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-11-01
|
Series: | Hereditary Cancer in Clinical Practice |
Online Access: | http://www.hccpjournal.com/content/8/1/9 |
id |
doaj-5afeb05417d74f69b1b043e0502601b1 |
---|---|
record_format |
Article |
spelling |
doaj-5afeb05417d74f69b1b043e0502601b12020-11-24T21:25:58ZengBMCHereditary Cancer in Clinical Practice1897-42872010-11-0181910.1186/1897-4287-8-9The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics programMukherjee AparnaMcGarrity Thomas JRuggiero FrancescaKoltun WalterMcKenna KevinPoritz LisaBaker Maria J<p>Abstract</p> <p>Background</p> <p>In 1996, the National Cancer Institute hosted an international workshop to develop criteria to identify patients with colorectal cancer who should be offered microsatellite instability (MSI) testing due to an increased risk for Hereditary Nonpolyposis Colorectal Cancer (HNPCC). These criteria were further modified in 2004 and became known as the revised Bethesda Guidelines. Our study aimed to retrospectively evaluate the percentage of patients diagnosed with HNPCC tumors in 2004 who met revised Bethesda criteria for MSI testing, who were referred for genetic counseling within our institution.</p> <p>Methods</p> <p>All HNPCC tumors diagnosed in 2004 were identified by accessing CoPath, an internal database. Both the Tumor Registry and patients' electronic medical records were accessed to collect all relevant family history information. The list of patients who met at least one of the revised Bethesda criteria, who were candidates for MSI testing, was then cross-referenced with the database of patients referred for genetic counseling within our institution.</p> <p>Results</p> <p>A total of 380 HNPCC-associated tumors were diagnosed at our institution during 2004 of which 41 (10.7%) met at least one of the revised Bethesda criteria. Eight (19.5%) of these patients were referred for cancer genetic counseling of which 2 (25%) were seen by a genetics professional. Ultimately, only 4.9% of patients eligible for MSI testing in 2004 were seen for genetic counseling.</p> <p>Conclusion</p> <p>This retrospective study identified a number of barriers, both internal and external, which hindered the identification of individuals with HNPCC, thus limiting the ability to appropriately manage these high risk families.</p> http://www.hccpjournal.com/content/8/1/9 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mukherjee Aparna McGarrity Thomas J Ruggiero Francesca Koltun Walter McKenna Kevin Poritz Lisa Baker Maria J |
spellingShingle |
Mukherjee Aparna McGarrity Thomas J Ruggiero Francesca Koltun Walter McKenna Kevin Poritz Lisa Baker Maria J The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program Hereditary Cancer in Clinical Practice |
author_facet |
Mukherjee Aparna McGarrity Thomas J Ruggiero Francesca Koltun Walter McKenna Kevin Poritz Lisa Baker Maria J |
author_sort |
Mukherjee Aparna |
title |
The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program |
title_short |
The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program |
title_full |
The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program |
title_fullStr |
The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program |
title_full_unstemmed |
The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program |
title_sort |
revised bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program |
publisher |
BMC |
series |
Hereditary Cancer in Clinical Practice |
issn |
1897-4287 |
publishDate |
2010-11-01 |
description |
<p>Abstract</p> <p>Background</p> <p>In 1996, the National Cancer Institute hosted an international workshop to develop criteria to identify patients with colorectal cancer who should be offered microsatellite instability (MSI) testing due to an increased risk for Hereditary Nonpolyposis Colorectal Cancer (HNPCC). These criteria were further modified in 2004 and became known as the revised Bethesda Guidelines. Our study aimed to retrospectively evaluate the percentage of patients diagnosed with HNPCC tumors in 2004 who met revised Bethesda criteria for MSI testing, who were referred for genetic counseling within our institution.</p> <p>Methods</p> <p>All HNPCC tumors diagnosed in 2004 were identified by accessing CoPath, an internal database. Both the Tumor Registry and patients' electronic medical records were accessed to collect all relevant family history information. The list of patients who met at least one of the revised Bethesda criteria, who were candidates for MSI testing, was then cross-referenced with the database of patients referred for genetic counseling within our institution.</p> <p>Results</p> <p>A total of 380 HNPCC-associated tumors were diagnosed at our institution during 2004 of which 41 (10.7%) met at least one of the revised Bethesda criteria. Eight (19.5%) of these patients were referred for cancer genetic counseling of which 2 (25%) were seen by a genetics professional. Ultimately, only 4.9% of patients eligible for MSI testing in 2004 were seen for genetic counseling.</p> <p>Conclusion</p> <p>This retrospective study identified a number of barriers, both internal and external, which hindered the identification of individuals with HNPCC, thus limiting the ability to appropriately manage these high risk families.</p> |
url |
http://www.hccpjournal.com/content/8/1/9 |
work_keys_str_mv |
AT mukherjeeaparna therevisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram AT mcgarritythomasj therevisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram AT ruggierofrancesca therevisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram AT koltunwalter therevisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram AT mckennakevin therevisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram AT poritzlisa therevisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram AT bakermariaj therevisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram AT mukherjeeaparna revisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram AT mcgarritythomasj revisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram AT ruggierofrancesca revisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram AT koltunwalter revisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram AT mckennakevin revisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram AT poritzlisa revisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram AT bakermariaj revisedbethesdaguidelinesextentofutilizationinauniversityhospitalmedicalcenterwithacancergeneticsprogram |
_version_ |
1725981740121456640 |